Sector News

Small molecule chief named head of gRED in rejig at the top of Genentech

December 15, 2014
Life sciences
There has been a change at the top of gRED. Having shepherded Genentech’s R&D operations through the takeover by Roche, Richard Scheller will retire at the end of 2014. Roche has lined up Michael Varney, Genentech’s head of small molecule drug discovery, to replace Scheller.
 
The rejig marks the first change at the top of Genentech Research and Early Development (gRED) since the early days of the Roche takeover, when the Swiss pharma fenced off the biotech’s early-stage R&D from its own operations. Scheller–who was Genentech’s chief scientific officer prior to the acquisition–was put in charge of the standalone R&D unit within one month of Roche closing the deal.
 
Under Scheller, gRED has propped up its parent company by delivering a string of cancer drugs–offset by the occasional failure such as MetMab–and developed promising candidates for diseases including age-related macular degeneration. Genentech even made a rare big-ticket deal, paying $725 million in cash–and agreeing to up to $1 billion in milestones–to takeover Seragon Pharmaceuticals and its breast cancer program.
 
The challenge of realizing the promise of Seragon’s science will now fall on Varney, who will take over as head of gRED in January. Varney is stepping up from his current position as head of small molecule drug discovery, a role he took in 2005. Back then, Genentech was just setting up its small molecule R&D operation. Now, it has named a man who has spent his career working on small molecules–first at Viracept developer Agouron Pharmaceuticals–as the head of its early-stage R&D operation.
 
By Nick Paul Taylor
 

comments closed

Related News

October 10, 2021

Nutraceutical giants’ partnerships inject life back into industry at Vitafoods

Life sciences

Some of industry’s biggest players are joining forces to bring cost-effective yet scientifically backed offerings to the nutraceuticals market. Co-creation is reinvigorating supplement innovation, pairing together companies’ diverse expertise, sales networks and clinical trial investments.

October 10, 2021

Pilot launch complete: GlaxoSmithKline’s malaria shot scores WHO backing for wider rollout in Africa

Life sciences

GlaxoSmithKline has spent many years developing and testing its world-first malaria vaccine, but even after a positive recommendation from European regulators in 2015, the shot still isn’t widely deployed. That’s set to change with the World Health Organization’s (WHO’s) blessing for the vaccine.

October 10, 2021

Henrietta Lacks’ estate sues Thermo Fisher for continued sale of HeLa cells without family consent

Life sciences

A sample of Henrietta Lacks’ tissue was taken from her cervix without her consent while she was undergoing cancer treatment at Johns Hopkins Hospital in 1951. Her cells have subsequently been used to develop the polio vaccine, HPV vaccines and gene-mapping techniques and continue to be sold for research purposes by Thermo Fisher Scientific.

Send this to a friend